



Contacts:

Investors

EVC Group

Douglas Sherk, 415-896-6820

Jennifer Beugelmans, 415-896-6820

Media

EVC Group

Jennifer Saunders

646-201-5431

FOR IMMEDIATE RELEASE

**PHARSIGHT STRENGTHENS MANAGEMENT TEAM**

*Company Promotes Dan Weiner to Chief Technology Officer,  
Dana C. Cambra Joins as Vice President of R&D*

**MOUNTAIN VIEW, Calif., April 5, 2007**– Pharsight Corporation (OTCBB: PHST), a leading provider of software and strategic services for optimizing clinical drug development, strengthened its management team today by promoting Daniel Weiner, Ph.D., to the new position of chief technology officer, and adding Dana C. Cambra as vice president, research and development. Both Dr. Weiner, 56, and Mr. Cambra, 48, will report to Shawn O'Connor, president and chief executive officer.

"Pharsight's growth requires a vital and far-reaching product vision. Dan's many accomplishments, both before and during his Pharsight career, make him ideal for the role of chief technology officer," said Shawn O'Connor. "Dan has a profound understanding of the analysis, modeling, data management, and reporting of kinetic and dynamic data used in drug development. Both industry and FDA recognize Dan as a leading authority in non-compartmental analysis, in compliant, high-productivity data management and reporting of concentration-time data, and in trial simulation. We look forward to Dan's continuing leadership and vision for our software products."

"Our search for a vice president of R&D focused on a successful track record in multidisciplinary product development. Dana Cambra brings expertise in software development, quality assurance, build and release, tools support, development labs, and project/product management," continued Mr. O'Connor. "Throughout his career, Dana has proven his ability to lead successful R&D efforts for a wide range of companies with growth opportunities similar to Pharsight's. We believe Dana will help Pharsight continue to innovate software for analysis, data management, model visualization, and validation of pharmacokinetic and pharmacodynamic data. We welcome Dana to Pharsight and look forward to his many contributions."

**Daniel Weiner**

Dr. Weiner has extensive drug development experience and has served as an expert consultant to FDA on pharmacokinetic modeling and bioequivalence assessment. Prior to his previous tenure with Pharsight as a senior vice president, Dr. Weiner held several management positions including head, biostatistics, Merrell Dow Pharmaceuticals; vice president, Statistical Consultants, Inc.; vice president, Syntex Development Research; senior vice president and principal scientist, Quintiles, and most recently, senior vice president and global head of clinical development at IVAX Research.

Dr. Weiner graduated from the University of Kentucky with a doctoral degree in mathematical statistics, with emphasis on compartmental modeling, as well as an M.S. in statistics, and a B.S. in mathematics. He is the co-author of “Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications.” Dr. Weiner is a past adjunct associate professor with the Colleges of Pharmacy and Environmental Health at the University of Cincinnati; a past president of the Greater Cincinnati Chapter of the American Statistical Association; a past vice-chair of the Biostatistics Subsection of PMA; and a past member of the Editorial Advisory Board for the Journal of Pharmaceutical Sciences.

### **Dana Cambra**

Mr. Cambra brings to Pharsight 20 years of success and leadership in engineering, quality and product/project management, including 8 years in executive management. Prior to joining Pharsight, Mr. Cambra was the vice president of engineering of Stentor, Inc., a leader in medical image and information management software that was sold to Phillips.

Prior to Stentor, Mr. Cambra was senior vice president of engineering and operations at Visto, Inc., where he led a successful co-development project with Handspring, providing exclusive “over the air” e-mail synchronization support for the Handspring Treo. Prior to Visto, he was vice president of engineering and operations for iScribe, a leading e-prescribing company that is now owned by Caremark. While there he successfully deployed Web and PDA (Palm and PocketPC) wireless and wireline ePrescribing and eChargeCapture applications to over 10,000 physicians. Earlier roles included software director for Acuson, a Siemens company that is a leader in ultrasound technology, where he was responsible for three different ultrasound platforms, and software engineering at General Electric where he built control and monitoring software for the nuclear power industry.

Mr. Cambra holds bachelors degrees in engineering and mathematics from the Massachusetts Institute of Technology, and a masters degree in engineering from the University of California, Berkeley.

### **About Pharsight Corporation**

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in

Mountain View, California. Information about Pharsight is available at <http://www.pharsight.com> .

# # #

.